New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 29, 2014
10:08 EDTAAPL, BRK.A, BA, GOOG, JNJApple is the world's most respected company, Barron's says
Apple (AAPL) moved to the first spot, from third place last year, in "The Top 100 Most Respected Companies" list. Berkshire Hathaway (BRK.A), last year's number one, dropped to second place. Boeing (BA) came in third, moving up from twenty six, Google (GOOG) maintained its position in fourth and Johnson & Johnson (JNJ) rounds up the top five, by moving up to fifth, from thirteenth, Barron's reports in its cover article. Reference Link
News For A;BA;GOOG;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
October 13, 2014
14:29 EDTBABoeing begins production on first 737 MAX parts
Boeing has started production of the first 737 MAX fuselage stringers at Boeing Fabrication Integrated AeroStructures in Auburn, Wash. Stringers run the length of the fuselage structure giving it stability and strength. After forming, Boeing will send the stringers to Spirit Aerosystems in Wichita, Kan. for incorporation into the first 737 MAX fuselage. From there the fuselage will be shipped to Boeing's Renton, Wash. facility where Boeing employees will build the 737 MAX. The program is on track to begin final assembly of the first 737 MAX in 2015. The airplane will be part of the flight test fleet and is scheduled to fly in 2016. The 737 MAX incorporates the latest technology CFM International LEAP-1B engines, Advanced Technology winglets and other improvements to deliver the highest efficiency, reliability and passenger comfort in the single-aisle market. The 737 MAX will be 14% more fuel-efficient than today's most efficient Next-Generation 737s – and 20% better than the original Next-Generation 737s when they first entered service.
14:24 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
13:53 EDTGOOGYouTube to open New York video production studio
Google's YouTube announced that it would open a new video production studio in New York next month. YouTube already has video production facilities in London, Los Angeles and Tokyo.
13:10 EDTGOOGGoogle's Schmidt says Amazon is company's biggest search rival, FT reports
Eric Schmidt, the executive chairman of Google (GOOG), says Amazon (AMZN) is his company's biggest rival in search, not Bing (MSFT) or Yahoo (YHOO), the Financial Times reports. Schmidt also argued in Berlin that Google should not be regulated "as if it were the gatekeeper of the internet," given the influence of Amazon and Facebook (FB). Reference Link
10:17 EDTBAEbola related weakness in aerospace stocks seen as buying opportunity
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:06 EDTGOOGQihoo 360 launches ad exchange platform, Marbridge Daily reports
Subscribe for More Information
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:57 EDTGOOGGoogle price target lowered to $650 from $685 at Cowen
Subscribe for More Information
07:53 EDTGOOGYouTube changes have diffused much of tension with copyright holders, FT says
YouTube, which implemented Content ID in 2007 to help producers manage their rights and generate revenues from copyright-infringing content, has hit $1B in payments to companies that participate in the program and Fred von Lohmann, legal director for copyright at Google, credits the program for diffusing much of the tension the site previously had with copyright holders, reported Financial Times. Via Content ID, copyright owners can “monetize” their content by allowing ads to be sold against it or have the video blocked and taken down and von Lohmann told Financial Times that the "vast majority" choose to monetize. Reference Link
07:26 EDTBACommercial aerospace stocks should be bought on any weakness, says Wells Fargo
Subscribe for More Information
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:22 EDTGOOGSony/ATV could ditch licensing firms due to streaming dollars, NY Post reports
Sony/ATV Music Publishing (SNE) is considering no longer dealing with performance rights groups BMI and ASCP, and instead negotiating directly with online music services like Pandora (P), YouTube (GOOG) and Spotify due to outdated rules and low royalties, the New York Post reports. Reference Link
07:15 EDTJNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
06:44 EDTGOOGGoogle testing feature that allows video chats with doctors, Engadget reports
Subscribe for More Information
06:44 EDTGOOGGoogle could announce new Nexus tablet on October 15, 9to5Google reports
Google's new Nexus tablet may be announced on Wednesday, October 15, 9to5Google reports, citing Bright Side of News. The HTC-made tablet is rumored to cost $400. Reference Link
October 12, 2014
19:41 EDTBABoeing and Garuda Indonesia announce $4.9B order
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use